Catalyst
Slingshot members are tracking this event:
Phase 1/2 trial of Corcept's (CORT) relacorilant plus abraxane in treating patients with solid tumors data to be realeased late 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 04, 2018
Occurred Source:
http://www.corcept.com/news_events/view/pr_1478031980.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Relacorilant, Abraxane, Solid Tumors
